An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients

Taphoorn, Martin J.B.; Claassens, L.; Aaronson, Neil K.; Coens, Corneel; Mauer, Murielle; Osoba, David; Stupp, Roger; Mirimanoff, R.O.; Bent, Martin J. van den; Bottomley, Andrew

doi:10.1016/j.ejca.2010.01.012

Cited by 305 publications

(211 citation statements)

References 15 publications

Supporting

Mentioning

193

Contrasting

Unclassified

Order By: Relevance

“…Prior to data collection, the Institutional Review Board of each participating center approved the study protocol. The EORTC QLQ-C30 is an internationally validated instrument commonly used to assess the QOL in patients with cancer (8), whereas the EORTC QLQ-BN20 is a validated questionnaire for patients with primary brain tumors (9). HRQOL was assessed using the Japanese version of QLQ-C30 (version 3.0) (8) and QLQ-BN20 (9).…”

Section: Methodsmentioning

confidence: 99%

Health-related quality of life in outpatients with primary central nervous system lymphoma after radiotherapy and high-dose methotrexate chemotherapy

Okita

Narita²,

Miyakita³

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Chemoradiotherapy for primary central nervous system lymphoma (PCNSL) is associated with a considerable risk of long-term neurotoxicity. The present study aimed to assess the health-related quality of life (HRQOL) of outpatients with PCNSL who have received radiotherapy and high-dose methotrexate (HDMTX) chemotherapy, and to determine the factors that cause a decline in HRQOL and interfere with home living. A total of 37 patients were surveyed 0.9-14.2 years after their initial diagnosis and treatment. Each patient completed a multi-part HRQOL questionnaire that was used to examine the associations of HRQOL scores with leukoencephalopathy, Karnofsky performance status (KPS) scores, age, history of recurrence and HDMTX-based chemoradiotherapy. The results demonstrated that the history of recurrence, number of cycles of MTX chemotherapy and age affected the development of leukoencephalopathy. Reductions in KPS score were associated with a history of recurrence (P=0.03), but not with leukoencephalopathy (P=0.8). KPS score, leukoencephalopathy and age were significantly associated with a decline in HRQOL score. A decline in the HRQOL associated with a reduction in KPS score was also observed by multivariate analyses. Deterioration of the HRQOL among outpatients with PCNSL post-chemoradiotherapy was significantly associated with older age (≥66 years) and decreased KPS score. Older patients with a history of recurrence had a higher risk for deteriorated QOL due to development of leukoencephalopathy. Therefore, it is recommended that clinicians monitor the KPS score among outpatients with PCNSL. QOL examination for older patients

show abstract

Section: Methodsmentioning

confidence: 99%

Health-related quality of life in outpatients with primary central nervous system lymphoma after radiotherapy and high-dose methotrexate chemotherapy

Okita

Narita²,

Miyakita³

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…[27][28][29] Patients completed the questionnaires without assistance. Five scales were prespecified for the primary analysis of deterioration-free survival: global health status, physical functioning, social functioning, motor dysfunction, and communication deficit.…”

Section: Assessmentsmentioning

confidence: 99%

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

Chinot¹,

Wick²,

Mason³

et al. 2014

N Engl J Med

2,136

1,618

View full text Add to dashboard Cite

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. Medicine, http://dx.doi.org/10.1056/NEJMoa1308345 New England Journal ofAccess to the published version may require subscription. N.B. When citing this work, cite the original published paper. Permanent link to this version:http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-89503T h e ne w e ngl a nd jou r na l o f m e dicine n engl j med 370;8 nejm

show abstract

“…The construction of this 30-item measure, designed to assess the HRQOL of cancer patients, is shown in Figure 1. The EORTC QLQ-BN20, specifically developed and validated for patients with brain cancer, includes 20 items assessing visual disorder, motor dysfunction, various disease symptoms, treatment toxicity, and future uncertainty [11] (Fig. 2).…”

Section: Assessing Hrqol: a Patient-reported Outcome Approachmentioning

confidence: 99%

Review on Quality of Life Issues in Patients with Primary Brain Tumors

2010

Self Cite

View full text Add to dashboard Cite

Health-related quality of life (HRQOL) has become an important outcome measure in clinical trials in primary brain tumor (i.e., glioma) patients, because they have an incurable disease. HRQOL is assessed using self-reported, validated questionnaires, addressing physical, psychological, emotional, and social issues. In addition to generic HRQOL instruments, disease-specific questionnaires have been developed, including for brain tumor patients. For the analysis and interpretation of HRQOL measurements, low compliance and missing data are methodological challenges. HRQOL in glioma patients may be negatively affected by the disease itself as well as by side effects of treatment. But treatment with surgery, radiotherapy, and chemotherapy may improve patient functioning and HRQOL, in addition to extending survival.Although HRQOL has prognostic significance in brain tumor patients, it is not superior to well-known clinical parameters, such as age and performance status. In clinical practice, assessing HRQOL may be helpful in the communication between doctor and patient and may facilitate treatment decisions. The Oncologist 2010;15:618 -626

show abstract

An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients

Cited by 305 publications

References 15 publications

Health-related quality of life in outpatients with primary central nervous system lymphoma after radiotherapy and high-dose methotrexate chemotherapy

Health-related quality of life in outpatients with primary central nervous system lymphoma after radiotherapy and high-dose methotrexate chemotherapy

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

Review on Quality of Life Issues in Patients with Primary Brain Tumors

Contact Info

Product

Resources

About